

# A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors

NCT05315167

---

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Zhuhai Yufan Biotechnologies Co., Ltd
Enrollment	267 participants

## Key Eligibility Criteria

---

### Inclusion (9)

- Histologically or cytologically confirmed locally advanced (unresectable) or metastatic r/r solid tumors for which no standard therapy is available or for whom standard therapy is considered unsuitable or intolerable.
  - Male or non-pregnant, non-lactating female subjects age ≥18 years.
  - ECOG Performance Status 0-1.
  - Has at least 1 measurable lesion as defined by RECIST 1.1 criteria .
  - Life expectancy of >3 months, in the opinion of the Investigator.
- ... and 4 more (see full listing online)

### Exclusion (9)

- History of another malignancy
  - Known symptomatic brain metastases requiring >10 mg/day of prednisolone.
  - Significant cardiovascular disease.
  - Known active HBV, HCV, AIDS-related illness.
  - Has received a live vaccine within 30 days.
- ... and 4 more (see full listing online)

## Locations (5 total)

---

The first affiliated hospital of Zhengzhou University, Zhengzhou, Henan, China  
West China Hospital of Sichuan University, Chengdu, Sichuan, China  
Cancer hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China  
... and 2 more locations